Brief: Hyloris Pharmaceuticals Net Loss Widens To EUR 8.2 Mln

Hyloris Pharmaceuticals SA

04/08/2021 06:29

Aug 4 (Reuters) - HYLORIS PHARMACEUTICALS SA  HYL.BR :
    * HALF YEAR REVENUE ROSE 922 PERCENT TO 838,000 EUR
    * REPORTS 2021 HALF-YEAR RESULTS: MULTIPLE POTENTIAL VALUE
INFLECTION POINTS AHEAD
    * EXPECTED TO START 2 CLINICAL STUDIES AND TO REPORT RESULTS
FROM
2 CLINICAL STUDIES BEFORE YEAR-END
    * EUR 53.47 MILLION IN CASH AND CASH EQUIVALENTS TO EXECUTE
AMBITIOUS GROWTH STRATEGY
    * ON TARGET TO GROW BROAD PRODUCT PIPELINE WITH AT LEAST 3
ADDITIONAL PROGRAMMES BEFORE END 2021
    * SIGNIFICANT EXPANSION OF COMMERCIAL FOOTPRINT OF
NON-OPIOID PAIN
TREATMENT MAXIGESIC® IV
    * COMPANY IS WELL-CAPITALISED TO ADVANCE ALL CURRENT
PIPELINE
ASSETS AS PLANNED AND EXECUTE ITS CURRENT BUSINESS PLAN WITH
EXPECTATION TO EXPAND PORTFOLIO TO 30 CANDIDATE - AND MARKETED
PRODUCTS BY 2024
    * REALISED A NET LOSS OF EUR 8,240 THOUSAND FOR SIX-MONTH
PERIOD
ENDING 30 JUNE 2021, COMPARED TO A NET LOSS OF EUR 3,742
THOUSAND FOR FIRST HALF-YEAR OF 2020.
    * OPERATING LOSS AMOUNTED TO EUR 7,913 THOUSAND FOR FIRST
HALF-YEAR OF 2021, COMPARED TO AN OPERATING LOSS OF EUR 3,633
THOUSAND FOR FIRST HALF-YEAR OF 2020
    * CURRENT CASH AND CASH EQUIVALENTS TOTALLED EUR 53,465
THOUSAND
ON 30 JUNE 2021, COMPARED TO EUR 66,783 THOUSAND ON 31 DECEMBER
2020

Source text for Eikon:  ID:nGNEbKRxl3 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))